Among 1,263 patients with T2DM, the most common antidiabetic medications prescribed for managing NASH were metformin, incretin mimetics/glucagon-like peptide 1 agonists, and sodium glucose co-transporter-2 inhibitors; pioglitazone was only used by 8% of patients (Table S4). Here, GCG is linked to metabolic dysfunction-associated steatohepatitis.